Home LiteratureArticle Details
PMID: 23475129 Published · ppublish English Journal Article Review

Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy.

Human vaccines & immunotherapeutics ·Vol. 9 ·No. 7 ·2013-07-00 ·Pages 1545-8

Browning MJ

Abstract

Fusions of antigen presenting cells and tumor cells have been investigated in animal models and phase I/II clinical trials as candidate cancer vaccines. In animal studies there have been numerous reports of induction of protective immunity against a wide range of tumor types. Results of clinical trials have been less dramatic, but tumor-specific immune responses have been reported in many patients, with clinical responses to the vaccination in a subset. In this commentary article, I review the current status of antigen presenting cell/tumor cell fusion vaccines for cancer immunotherapy.

Keywords
antigen presenting cell cancer fusion hybrid tumour vaccine
MeSH Terms
Animals Antigen-Presenting Cells/immunology CD4-Positive T-Lymphocytes/immunology CD8-Positive T-Lymphocytes/immunology Cancer Vaccines/immunology Cell Fusion Cell- and Tissue-Based Therapy Humans Hybrid Cells/immunology Immunotherapy/methods Lymphocyte Activation Mice Neoplasms/immunology,prevention & control,therapy
Chemicals
Cancer Vaccines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Browning Michael J
Department of Infection; Immunity and Inflammation; University of Leicester; Leicester, UK; Department of Immunology; Leicester Royal Infirmary; Leicester, UK.
References (40)
40 references, click to expand
  1. Cancer immunoediting: from immunosurveillance to tumor escape.
    Nat Immunol. 2002 Nov;3(11):991-8 PMID: 12407406
  2. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells.
    Science. 1994 Jan 28;263(5146):518-20 PMID: 7507262
  3. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    J Immunol. 1998 Nov 15;161(10):5516-24 PMID: 9820528
  4. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
    Br J Haematol. 2004 May;125(3):343-52 PMID: 15086415
  5. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts.
    Leuk Res. 2004 Dec;28(12):1303-12 PMID: 15475072
  6. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma.
    Int J Cancer. 2000 Mar 1;85(5):618-26 PMID: 10699939
  7. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
    Hum Gene Ther. 2003 Mar 20;14(5):483-94 PMID: 12691613
  8. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine.
    J Clin Invest. 2004 May;113(9):1307-17 PMID: 15124022
  9. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells.
    Mol Ther. 2003 Apr;7(4):498-505 PMID: 12727113
  10. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Int J Oncol. 2006 Sep;29(3):531-9 PMID: 16865268
  11. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma.
    Br J Urol. 1998 Oct;82(4):487-93 PMID: 9806175
  12. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells.
    J Immunol. 2003 Feb 15;170(4):1980-6 PMID: 12574367
  13. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells.
    J Immunother. 2002 Sep-Oct;25(5):421-8 PMID: 12218780
  14. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.
    Blood. 2002 Apr 1;99(7):2512-7 PMID: 11895787
  15. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer.
    Cancer Immunol Immunother. 2004 Dec;53(12):1111-8 PMID: 15185011
  16. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
    Blood. 2010 Feb 4;115(5):925-35 PMID: 19880495
  17. In vitro evaluation of human hybrid cell lines generated by fusion of B-lymphoblastoid cells and ex vivo tumour cells as candidate vaccines for haematological malignancies.
    Vaccine. 2012 Oct 12;30(46):6578-87 PMID: 22939910
  18. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.
    Immunobiology. 2012 Jul;217(7):719-29 PMID: 22305004
  19. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
    Cancer Immunol Immunother. 2007 Jul;56(7):1025-36 PMID: 17131118
  20. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.
    Immunology. 1999 Dec;98(4):541-50 PMID: 10594686
  21. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Vaccine. 2012 Jun 19;30(29):4394-7 PMID: 22122856
  22. Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: a pilot phase I study.
    J Immunother. 2001 Jan-Feb;24(1):19-26 PMID: 11211145
  23. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells.
    Nat Med. 1997 May;3(5):558-61 PMID: 9142127
  24. Development of tumor B-cell lymphocyte hybridoma (TBH) autovaccination. Results of a phase I-II clinical trial.
    Transfus Sci. 1996 Dec;17(4):643-9 PMID: 10168565
  25. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28.
    J Immunother. 2010 Feb-Mar;33(2):155-66 PMID: 20145548
  26. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.
    Blood. 2010 May 13;115(19):3869-78 PMID: 20071660
  27. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity.
    Eur J Clin Invest. 2003 Oct;33(10):897-904 PMID: 14511362
  28. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    J Immunol. 2005 Feb 1;174(3):1274-80 PMID: 15661883
  29. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
    Clin Cancer Res. 2005 Jan 1;11(1):58-66 PMID: 15671528
  30. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
    Immunology. 2003 Jun;109(2):300-7 PMID: 12757626
  31. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
    Cancer Res. 2007 Jun 1;67(11):5443-53 PMID: 17545626
  32. Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice.
    J Immunother. 2006 Mar-Apr;29(2):175-87 PMID: 16531818
  33. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.
    Clin Cancer Res. 2004 Jul 15;10(14):4699-708 PMID: 15269142
  34. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
    Cytotherapy. 2012 Jan;14(1):80-90 PMID: 21942841
  35. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
    Blood. 2011 Jan 13;117(2):393-402 PMID: 21030562
  36. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
    J Immunother. 2007 Oct;30(7):749-61 PMID: 17893567
  37. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.
    Vaccine. 2005 Mar 18;23(17-18):2367-73 PMID: 15755630
  38. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line.
    Eur J Immunol. 1982 Aug;12(8):641-8 PMID: 7140810
  39. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients.
    Int J Cancer. 2004 Jul 10;110(5):730-40 PMID: 15146563
  40. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
    Br J Haematol. 2005 May;129(3):340-9 PMID: 15842657
Article Info
Journal
Human vaccines & immunotherapeutics
Abbr.
Hum Vaccin Immunother
ISSN
2164-554X
DOI
10.4161/hv.24235
Published
2013-07-00
Epub
2013-00-08
Pages
1545-8
Language
English
Region
United States
NLM ID
101572652
PMCID
PMC3890217
Subset
IM
External Links
PubMed source DOI: 10.4161/hv.24235 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2